Author:
Zhang Ying,Yue Weihua,Li Jie
Abstract
Abstract
Background
Given the inconsistencies in current studies regarding the impact of FKBP5 gene polymorphisms on depression, arising from variations in study methods, subjects, and treatment strategies, this paper provides a comprehensive review of the relationship between FKBP5 gene polymorphisms and genetic susceptibility to depression, as well as their influence on response to antidepressant treatment.
Methods
Electronic databases were searched up to April 11, 2023, for all literature in English and Chinese on depression, FKBP5 gene polymorphisms, and antidepressant treatment. Data extraction and quality assessment were performed for key study characteristics. Qualitative methods were used to synthesize the study results.
Results
A total of 21 studies were included, with the majority exhibiting average to moderate quality. Six SNPs (rs3800373, rs1360780, rs9470080, rs4713916, rs9296158, rs9394309) were broadly implicated in susceptibility to depression, while rs1360780 and rs3800373 were linked to antidepressant treatment sensitivity. Additionally, rs1360780 was associated with adverse reactions to antidepressant drug treatment. However, these associations were largely unconfirmed in replication studies.
Conclusions
Depression is recognized as a polygenic genetic disorder, with multiple genes contributing, each exerting relatively small effects. Future studies should explore not only multiple gene interactions but also epigenetic changes. Presently, research on FKBP5 in affective disorders remains notably limited, highlighting the necessity for further investigations in this domain.
Publisher
Springer Science and Business Media LLC
Reference56 articles.
1. Clark SLHM, Chan RF, et al. A methylation study of long-term depression risk. Mol Psychiatry. 2020;25(6):1334–43.
2. VG F. Pharmacological sex hormone manipulation as a risk model for depression. J Neurosci Res. 2020;98(7):1283–92.
3. Zhdanava M, Pilon D, Ghelerter I, Chow W, Joshi K, Lefebvre P, Sheehan JJ. The prevalence and national burden of treatment-resistant depression and major depressive disorder in the United States. J Clin Psychiatry. 2021;82(2):29169.
4. Gharraee BTK, Sheybani F, et al. Prevalence of major depressive disorder in the general population of Iran: a systematic review and meta-analysis. Med J Islam Repub Iran. 2019;33:151.
5. Kraus CKB, Lanzenberger R, Zarate CA Jr, Kasper S. Prognosis and improved outcomes in major depression: a review. TranslPsychiatry. 2019;9(1):127.